Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence
Studying Langerhans cell histiocytosis
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- Shanghai Changzheng Hospital
- Intervention
- Prednisone(drug)
- Enrollment
- 118 enrolled
- Eligibility
- 2-17 years · All sexes
- Timeline
- 2023 – 2027
Study locations (1)
- Shanghai Changzheng Hospital, Shanghai, Shanghai Municipality, China
Collaborators
First Affiliated Hospital of Zhejiang University · Peking University Third Hospital · National Sun Yat-sen University · Beijing Children's Hospital · Henan Cancer Hospital · Tianjin Hospital · First Affiliated Hospital, Sun Yat-Sen University · Second Hospital of Jilin University · Peking University People's Hospital · Jinling Hospital, China · The First Affiliated Hospital of Nanchang University · The Third Affiliated Hospital of Southern Medical University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06078969 on ClinicalTrials.govOther trials for Langerhans cell histiocytosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07371182Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone LesionsWest China Second University Hospital
- RECRUITINGNANCT07431060Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell HistiocytosisWest China Second University Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT07204041Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCHCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPHASE2NCT07022834Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in ChildrenWest China Second University Hospital
- RECRUITINGPHASE2NCT07187193Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCHCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ENROLLING BY INVITATIONPHASE1NCT06902792Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and AdolescentsSecond Affiliated Hospital of Wenzhou Medical University
- RECRUITINGPHASE2NCT06582745Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, TrametinibCook Children's Health Care System
- RECRUITINGPHASE2NCT05828069A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistiocytosisNational Cancer Institute (NCI)